Tags: Clinical Trials

announcements

New Investments Fund Research Ranging from Novel Treatments for Postoperative Cognitive Dysfunction

The Alzheimer's Drug Discovery Foundation (ADDF) announces seven new investments, including clinical trials, novel drug programs, and a prevention program, which reflects the comprehensive nature of the ADDF's funding strategy.

announcements

$2.5 Million in New Funding Exemplifies ADDF’s Strategy

We announce $2.5 million in new funding, which reflects the comprehensive nature of our strategy to prevent and treat Alzheimer’s disease. 

blog

Alzheimer’s Clinical Trials, Explained

Learn about clinical trials, an important and growing part of our funding at the Alzheimer’s Drug Discovery Foundation. 

blog

ADDF Grantees Headline NIH Alzheimer's Summit

ADDF-supported research was at the forefront of the Summit and the National Plan to Address Alzheimer's.

blog

Meeting the Challenge of CTE

For CTE Awareness Day, we highlight our support of diagnostic tools and treatments for this disease. 

announcements

$1.8 Million in New Funding Supports Clinical Stage Treatments

The ADDF announces nearly $1.8 million in new funding, which reflects our commitment to advancing drugs in or near human clinical trials.

blog

Top Five Alzheimer’s Advances in 2017

Our top five advances in 2017 spotlight the substantial progress we have made toward conquering Alzheimer’s and other neurodegenerative diseases.

blog

Closing in on a Cure: Dr. Roberta Diaz Brinton and Allopregnanolone

With funding from the ADDF since 2004, Dr. Roberta Diaz Brinton has developed what may become the first ever regenerative treatment for Alzheimer's disease.

announcements

Three New Grants Keep Promising Programs Forging Ahead

The Alzheimer’s Drug Discovery Foundation (ADDF) announces three new investments, all of which are for programs that the ADDF previously funded.

announcements

New Report Highlights Innovation in Alzheimer’s Clinical Trials

Closing in on a Cure: 2017 Alzheimer’s Clinical Trials Report surveys the 126 drugs in clinical development for Alzheimer’s disease—20% of which received support from the Alzheimer’s Drug Discovery Foundation.